semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Presence of at least two out the following cardinal signs: resting tremor, cogwheel rigidity, bradykinesia, asymmetrical onset of symptoms and symptomatic response to L-dopa (levodopa)  Previous thalamotomy on the implanted sides Significant brain atrophy or structural damage seen on CT or MRI Marked cognitive dysfunction Active psychiatric symptoms Concurrent neurological disorders Other uncontrolled medical disorders
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Patients With Cancer Pain Patient aged over 18. 2. Followed in the participant comprehensive cancer center. 3. All cancer types, location and stage. 4. Patient under any anticancer treatment (including hormonal therapy) and has stopped his treatment in less than a year. 5. Patient experiencing cancer pain and/or his treatments for 3 months or more. 6. All previous and concomitant treatments are accepted. 7. Participation to another clinical trial is accepted. 8. Patient has accepted to participate to the study and signed informed consent form or his legal representative. 9. Patient affiliated to the social security healthcare  Cognitive impairment preventing to understand the patient education program. 2. Language barrier preventing to understand the patient education program. 3. Physical impairment preventing patient to attend to the patient education program
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Endothelial Dysfunction We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital  History of Coronary artery disease History of Peripheral Arterial Disease History of Heart failure History of Stroke hepatic failure renal failure active neoplasia poorly controlled DM, defined as Hba1C>7%
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 55.0-65.0,  Parkinson's Disease Physical Exercise Participants were diagnosed primary PD according to the 2015 MDS diagnostic Participants are between 55 and 65 years old  Severe heart liver dysfunction kidney dysfunction severe cognitive dysfunction severe anxiety and depression history of mental illness history of cerebral infarction or ischemic attack in the past three months acute myocardial infarction or acute coronary in the past three months Parkinson's Pulse syndrome medication history (drugs that improve blood circulation in the brain and increase the excitability of the nervous system)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-100.0,  Irreversible Pulpitis Patient in American Society of Anesthesiologists I or II condition Patient who comes to the emergency room with irreversible pulpitis in a single tooth Patients of age >20 years Positive response to the vitality test and bleeding after pulp exposure  American Society of Anesthesiologists patients>II Pharmacological allergies that contraindicate the intervention Teeth with negative vitality test and no bleeding after pulp exposure Signs of concomitant periodontal infection such as swelling or fistula Teeth with immature roots Patients who are medicated with anxiolytics Abuse of psychotropic drugs or medication that may alter the perception of pain 15 days before the intervention Pregnant or breast-feeding women Interventions with conscious sedation Pathological mental state (dementia, psychosis)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  Parkinson Disease Parkinson disease diagnosed by neurologist with Hoehn & Yahr stage 2 or 3 Having a 30-meter walking ability  Significant neurological condition (other than Parkinson's disease) Musculoskeletal conditions affecting gait, balance or functions Had received deep brain stimulation surgery Cognitive impairment with Montreal Cognitive Assessment score <24 Present with on-off motor fluctuations
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Parkinson Disease Ability to give informed consent for the study Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical Patient has requested surgical intervention with deep brain stimulation for their disorder No movement -elated abnormalities that suggest an alternative diagnosis or contraindicate surgery Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA) Signed informed consent Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment Age 21-75 Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist  Coagulopathy, anticoagulant medications, uncontrolled hypertension, history of seizures, heart disease, or other medical conditions considered to place the patient at elevated risk for surgical complications Evidence of a psychogenic movement disorder: Motor symptoms that remit with suggestion or "while unobserved", symptoms that are inconsistent over time or incongruent with clinical condition, plus other manifestation such as "false" signs, multiple somatizations, or obvious psychiatric disturbance Pregnancy: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure Significant untreated depression (BDI-II score >20). History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS) Any personality or mood symptoms that study personnel believe will interfere with study requirements Subjects who require electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) or diathermy Implanted stimulation systems such as; cochlear implant, pacemaker, defibrillator, or neurostimulator Previous cranial surgery Drug or alcohol abuse Meets for Parkinson's disease with mild cognitive impairment (PD-MCI). These are: performance of more than two standard deviations below appropriate norms, for tests from two or more of these five cognitive domains: attention, executive function, language, memory, and visuospatial tests
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Parkinson Disease With Dementia Fulfill the Movement Disorder Society Clinical Diagnostic for Parkinson's disease, age between 45-80 years old. 2. With mild cognitive impairment or dementia (Clinical Dementia Rating Scale >= 0.5)  People who have 1. pre-existing and active major neurological diseases other than PD 2. with a previous history of seizures 3. with implanted metallic objects that would contraindicate rTMS 4. unable to perform fMRI 5. with skin damage on the stimulation area 6. with multiple sclerosis 7. with large ischemic scars 8. with a family history or medical history of seizures, epilepsy 9. brain damage may affect the threshold for inducing epilepsy 10. taken tricyclic antidepressants, analgesics, or anything that may lower the threshold for inducing epilepsy 11. with sleep disorders during the rTMS treatment 12. with severe alcohol abuse or use of epilepsy drugs 13. with severe heart disease or uncontrollable migraine caused by high intracranial pressure 14. who are actively suicidal during the trial period, have recurring major medical disorders, or with neurological co-morbidities such as space occupying lesions, CVA, aneurysms etc
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Shoulder Osteoarthritis First-line reverse prosthesis 2. Without prosthetic history 3. Patient who has given his consent to participate in the observational study after being informed by the surgeon 4. Patient living in France and able to answer the questionnaire alone. 5. Subject affiliated to a social security scheme or beneficiary of such a scheme 6. Lack of participation in another clinical study  Minor patient 2. Major subject protected by law, under curatorship or tutorship 3. Anterior prosthesis 4. Infection 5. Parkinson's, degenerative neurological disease 6. Pregnant or breastfeeding woman
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.083-0.917,  Child Mortality Community Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins) Verbal consent of the community leader is obtained for children Aged 1 to 11 months Living in one of the communities participating in the study  Community • Inaccessible or unsafe for the study team for children: • Known allergy to macrolides
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Parkinson Disease Idiopathic Parkinson's disease diagnosis according to Parkinson's Disease Society Brain Bank of London Active treatment with levodopa Stages 1, 2, and 3 according to Hoehn and Yahr Classification  Severe cognitive impairment defined as ≤ 20 in Montreal Cognitive Assessment Score greater than or equal to 6 on the geriatric depression scale Severe respiratory and / or cardiovascular conditions Visual and / or auditory deficit that cannot be corrected with glasses or a hearing aid Other previously detected orthopedic or neurological diseases, other than Parkinson's Disease, that may interfere with the individual's performance Previous experience with Microsoft XBOX Kinect® games And being in rehabilitation in another location concomitant to this training
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Aggravated patients aged 18-years old or older with moderate to severe dyskinesia and/or motor fluctuations with incomplete or poor response to adjustments in time and dose of levodopa and other anti-parkinsonian agents such as entacapone, rasagiline, dopamine receptor agonists and amantadine in 1-2 months prior to enrollment; defined by a Movement Disorders Society Unified Parkinson´s Disease Rating Scale (MDS-UPDRS) part IV score equal or higher than 8 following pharmacological adjustments  patients with chronic renal failure, decompensated heart failure, colonic abnormalities precluding the use of evacuating enema, known allergies to prescribed medications to reduce microbiota load and patients who declined to participate in the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease, Idiopathic *Inclusion 1. Male or Female; 2. Clinically defined idiopathic Parkinson's Disease (PD); 3. Brain MRI performed in routine care in the 12 months preceding inclusion; 4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before (no time limit), confirming presynaptic dopaminergic denervation; 5. Hoehn & Yahr score: 1 to 3; 6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted); 7. Neuro-cognitive disorders: absent or minor (according to DSM5); 8. Sufficient written and oral expression in French; 9. Covered by a health insurance system; 10. Written informed consent signed by the patient; 11. Presence of a caregiver. *  Psychiatric comorbidity (except anxiety or mild to moderate depression); 13. Neurological comorbidity, if significant; 14. Brain MRI showing: 1. significant cerebrovascular pathology (Fazekas I admitted), 2. another brain disease, including stroke. 15. Major cognitive impairment; 16. Absolute and "Red flags" of the 2015 orienting towards another degenerative pathology of the extrapyramidal system Cerebellar syndrome Vertical oculomotricity disorders on clinical examination Motor symptoms restricted to the lower limbs Bilateral and perfectly symmetrical parkinsonism Early dystonia Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD) Progressive aphasia or apraxia Moderate or severe postural instability and / or early falls
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Parkinson Disease Participants must meet the Movement Disorders Society (MDS) diagnostic for clinically established Parkinson disease. 2. Able to provide signed informed consent (in English or Spanish) 3. Mild, moderate, or severe Parkinson disease, able to ambulate (Hoehn and Yahr stages I-IV) 4. Taking instant release oral carbidopa/levodopa therapy 5. Either not taking, or on stable doses of any of the following antiparkinsonian medications: dopamine agonists, monoamine oxidase B (MAO-B) inhibitors or catecholamine O-methyl transferase (COMT) inhibitors  Other neurological conditions including but not limited to stroke, dementia (including Parkinson disease dementia), or traumatic brain injury 2. Co-existent major psychiatric disease 3. Uncontrolled, active medical conditions (e.g., heart, kidney, or liver failure, diabetes, etc.) 4. Status post deep brain stimulation (DBS) device placement 5. Any other condition, that in the opinion of the investigators, would place the participant at risk
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson's Disease (PD) Completion of the parent study, Study M15-736  Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason